ProCE Banner Activity

Approaches to Individualized Treatment for Chronic Lymphocytic Leukemia: Expert Guidance on Sequencing Therapy, Novel Agents, and Their Combinations

Slideset Download
Download these slides from our live satellite symposium on CLL to review the most recent clinical data on new agents in both frontline and relapsed/refractory CLL.

Released: September 26, 2019

Expiration: September 24, 2020

Share

Faculty

Jeremy S Abramson

Jeremy S Abramson, MD, MMSc

Director, Center for Lymphoma
Mass General Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

William G. Wierda

William G. Wierda, MD, PhD

Associate Professor of Medicine
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Provided by

Provided by National Comprehensive Cancer Network.
ProCE Banner

Faculty Disclosure

Primary Author

Jeremy S Abramson, MD, MMSc

Director, Center for Lymphoma
Mass General Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc, has disclosed that he has received consulting fees from AbbVie, Bayer, Celgene, EMD Sereno, Genentech, Janssen, Karyopharm, Kite, and Roche.

William G. Wierda, MD, PhD

Associate Professor of Medicine
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

William G. Wierda, MD, PhD, has disclosed that he has received consulting fees from Genzyme and funds for research support from AbbVie, Acerta, Cyclacel, Genentech, Gilead Sciences, GlaxoSmithKline/ Novartis, Janssen, Juno, Karyopharm, Kite, Loxo, Miragen, Oncternal, Pharmacyclics, Sunesis, and Xencor.